Chronoscale Holdings Corp quarterly report, Q1 FY2021

Ekso Bionics Holdings, Inc. — Q1 2021 Form 10-Q

Filing identity: The supplied filing is for Ekso Bionics Holdings, Inc. (Nasdaq: EKSO), not Chronoscale Holdings Corp. It reports the unaudited three months ended March 31, 2021; amounts below are in thousands of dollars unless stated otherwise.

Business context and results

Ekso designs, sells and rents exoskeletons for medical rehabilitation (EksoHealth) and industrial use (EksoWorks). Q1 revenue increased 30% year over year, primarily from higher EksoHealth device sales as business conditions began to normalize following COVID-19 disruptions.

MetricQ1 2021Q1 2020
Revenue$1,910$1,468
Gross profit / margin$1,235 / 65%$637 / 43%
Operating expenses$4,374$5,418
Operating loss($3,139)($4,781)
Net loss($3,670)($2,534)
Basic and diluted loss per share($0.34)($0.44)
Cash used in operations($2,000)($1,722)

Gross margin improvement reflected higher EksoNR selling prices, a greater share of medical device sales, lower EVO production costs and improved service margins. Operating expenses fell 19%, mainly due to prior-year workforce reductions and lower selling, development and legal costs. Net loss increased despite the narrower operating loss, chiefly because Q1 2020 included a $2,519 warrant revaluation gain versus only $11 in Q1 2021; Q1 2021 also had higher foreign-currency remeasurement expense.

Revenue mix and financial position

  • EksoHealth revenue was $1,727, up from $1,191; EksoWorks revenue was $183, down from $277. Medical device revenue totaled $1,117 versus $561, while service and support revenue was $488 versus $469.
  • Cash at quarter-end was $49,539, compared with $12,862 at December 31, 2020. Working capital was $48,600. Approximately $2,000 was restricted under the bank loan liquidity covenant, leaving estimated unrestricted cash of $47,539.
  • Cash from financing was $38,712, including net proceeds from the February public offering, ATM share sales and warrant exercises. The February offering raised $40,000 gross; the company also received $1,417 from warrant exercises and $791 net from ATM sales.
  • Total liabilities were $15,529. Notes payable were approximately $3,076 on the balance sheet, including an $814 current portion; the secured Pacific Western Bank term loan matures in August 2023, and the PPP loan’s forgiveness was unresolved. Lease liabilities totaled $646.
  • Deferred revenue was $3,137; management expected to recognize $1,193 during the remainder of 2021, $964 in 2022 and $980 thereafter. Non-cancellable rental backlog was $890.

Changes, outlook and risks

Management said demand had been affected by the pandemic, including delayed capital spending at rehabilitation facilities, but reported a substantial increase in onsite demonstrations in Q1 compared with the prior three quarters combined and expected more in-person activity as conditions improved. The filing provides no numerical revenue, earnings or cash-flow guidance. Management believed unrestricted cash would fund operations beyond one year from issuance of the financial statements, while noting continuing operating losses and cash use.

Key risks include uncertain COVID-19 effects and customer adoption; long and variable sales cycles; regulatory approvals and reimbursement; competition and product development; foreign-exchange exposure; and the need for future financing. The company reported two customers each contributing at least 10% of Q1 revenue (14% and 11%), and one customer representing 16% of receivables. It had $919 of purchase obligations due within a year. Management reported no pending legal proceedings expected to have a material adverse effect and no material changes to previously disclosed risk factors. Disclosure controls were assessed as effective.

Important facts for investors to verify

  • Whether device-sales growth and the improvement in gross margin persist as pandemic-related disruptions ease.
  • Operating cash burn and whether the reported cash balance supports the company’s stated runway, including the $2,000 covenant restriction.
  • Potential dilution and cash obligations from outstanding warrants, including liability-classified warrants and their valuation assumptions.
  • The outcome and timing of the PPP loan forgiveness application; the filing states forgiveness was not assured.
  • Exposure to customer concentration, foreign-currency movements and the listed purchase and royalty commitments.
Disclaimer:
This AI-generated summary by MetaQuotes is based on SEC filings and may contain errors. Verify important details against the original SEC filings.